Hospital for Special Surgery, Weill Cornell Medicine Jersey City, NJ, United States
Disclosure information not submitted.
Bella Mehta1, Yi Yiyuan2, Chloe Heiting3, Kaylee Ho2, Susan Goodman3, Peter Sculco3, Fei Wang2, Rich Caruana4, Peter cram5 and Said Ibrahim6, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, NY, 4Microsoft, Redmond, WA, 5The University of Texas Medical Branch, Galveston, TX, 6Northwell Health, New Hyde Park, NY
Background/Purpose: Rates of total knee arthroplasty (TKA) in the United Stateshave risen, coupled with increasing demand for TKAs in younger patients.1Althoughrates of postoperative complications in TKA have decreased significantly,2 they remaina significant concern for patients and clinicians. In light of these changing trends in TKA use and outcomes, we sought to understand how risk for adverse TKA outcomes changes with age using machine learning algorithms.
Methods: We studied patients undergoing TKA from the Pennsylvania Health Care Cost Containment Council (PHC4) Database, 2012-2018.Our primary variable of interest was age as a risk factor for the binary outcomes of 90-day readmission, 90-day mortality, 1-year revision, and the continuous outcome length of stay (LOS). Our model included patient-level demographics and covariates, including sex, race, discharge location, and insurance. We trained explainable boosting machines (EBMs)to predict risk (70% train:30% test) for the aforementioned outcomes.3For binary outcomes, we stratified the training data by outcome for balance. EBMs are highly accurate, interpretable models that are flexible in visualizing the dependent variables and handle collinearity well which is important in TKA. We report test AUROCs and R2as evaluation metrics for predictive performance of the models, and further include partial dependency plots which explain the relationship of age with these outcomes.
Results: We had a cohort of 227,959TKA patients, with a median age of 65 years with 90.1% White and 55% Medicare-insured (Table 1).90-day readmission was observed in 7.49%, 90-day mortality in 0.22%, and 1-year revision in 0.79%. Predictive performance of adverse outcomes was strongest for 90-day mortality (AUROC=0.74), followed by 1-year revision (AUROC=0.64), 90-day readmission (AUROC=0.62), and LOS (RMSE=0.36, R2=0.13). Age was among the most important factors for predicting all outcomes and its relationship with the outcomes is detailed in the partial dependency plots in Figure 1.Predicted risk of90-day mortality increases significantly after the age of 77.5 years, whereas90-day readmission increases after the age of 73.5 years, and LOS risk increases at 73.5 years. However, with 1-year revision the risk decreases after the age of 63.5 (Figure 1).
Conclusion: We determined that the effect of age as a risk factor for poor TKA outcomes changes dramatically at specific time points, thus demonstrating that there is a nonlinear relationship between age and TKA outcomes. Traditional regression models have always been understood to have a proportionate increase in risk as age increases. However, our study gives nuance to this understanding and can help physicians and patients in decision-making when trying to quantify risks related to aging as they consider TKA as a treatment option.
References
Ravi B et al. The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007. PMID:23218428
Singh JA et al. Rates of Total Joint Replacement in the United States: Future Projections to 2020–2040 Using the National Inpatient Sample. PMID:30988126
Nori H et al. InterpretML: A Unified Framework for Machine Learning Interpretability. arXiv:1909.09223
Table 1: Cohort Characteristics by Outcome
Figure 1: Partial dependency plots to understand the marginal effect of age (years) on (A) 90-day mortality, (B) 90-day readmission, (C) 1-year revision, and (D) length of stay from the supervised explainable boosting machine models. Y-axis score is shown in log scale. Vertical lines demonstrate where risk score is equal to 0, and show the age of the average contribution to risk.
B. Mehta: Janssen, 1, Novartis, 5; Y. Yiyuan: None; C. Heiting: None; K. Ho: None; S. Goodman: NIH, 5, Novartis, 5; P. Sculco: DePuy Synthes, 2, EOS Imaging, 2, Intellijoint Surgical, 2, 5, Lima Corporate, 2, Zimmer Biomet, 2, 5; F. Wang: None; R. Caruana: None; P. cram: None; S. Ibrahim: None.